The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

A new type of antibiotic for treatment of urinary tract infections in women could also work against gonorrhea infections, a ...

77%), regardless of whether the pathogens were susceptible or resistant to amoxicillin-clavulanate. Persistent UTIs occurred in 8 amoxicillin-clavulanate recipients and 1 ciprofloxacin recipient ...

for uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older. The small-molecule drug is the first in a new class of oral antibiotics for ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs). In clinical trials ...

In kids with a febrile urinary tract infection (UTI), an individualized duration of antibiotics led to an increased risk of recurrent UTI compared with a 10-day course. However, the individualized ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.